Report Overview

The Australian Huntington Disease (HD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Huntington disease (HD) is an inherited condition characterized by the progressive degeneration of neurons within certain areas of the brain (e.g., basal ganglia, cerebral cortex). People with HD usually live for about 15 to 20 years after the condition begins. Signs and symptoms usually develop between ages 35 to 44 years and may include uncontrolled movements, loss of intellectual abilities, and various emotional and psychiatric problems.

About six people per 100,000 are affected by Huntingtons Disease. In Australia over 2,500 people have Huntingtons Disease.



Market Growth Drivers

High unmet needs within the market present a key commercial opportunity to develop breakthrough disease-modifying therapies. The introduction of disease-modifying drugs is poised to transform the market landscape. With ongoing research, there are increasingly significant opportunities for drug companies to develop new drugs with novel mechanisms of action.

The Huntingtons Disease Therapeutics market is expected to witness novel product launches, including approval of several disease-modifying therapies. Current research in HD focuses on using novel treatments such as immuno-modulating therapies, gene therapy (using antisense oligonucleotides, micro RNAs (miRNA), mRNA splicing, and zinc-finger DNA binding protein).

Increasing incidence and prevalence of Huntington Disease is one of the major key driver of HD market growth over the forecast period. Wave Life Sciences and Roches antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

However, increase in cost of medical treatment, less prominent reimbursement policies and occurrence of side effects in related current available treatments may hamper the Huntington disease treatment market growth.